The emergence of yet another COVID strain could ultimately bring investors back to this synbio stock…
Over the past several days, reports of a new strain – now referred to as “Deltacron” – suggest the virus won’t be going away anytime soon.
And it even forced the Chinese government to once again enter a renewed lockdown to prevent its rapid spread, indicating the world will likely remain reliant on MRNA’s vaccines for years to come.
This was made abundantly clear following MRNA’s most recent earnings report as well…
In late-February, the synbio company reported earnings per share of $11.29, beating Wall Street’s estimates of $9.96.
Meanwhile, MRNA’s revenue of $7.21 billion also came in well above the expectation of $6.8 billion – signaling demand for its vaccines and other mRNA-based treatments remains elevated.
And with many health experts forecasting COVID-19 strains becoming endemic like the flu, this demand for updated vaccines from synbio companies like MRNA will continue over the long term.
Apple to shock world with one last tech marvel from Steve Jobs?
Sponsored
Before Steve Jobs died…
He actually left behind one more radical idea for Apple.
An idea so big and so novel, it could completely change the way we see Apple as a company forever.
For over 7 months, my team and I have been piecing together the breadcrumbs… clues left in plain sight…
And our research indicates that this last technological marvel from the mind of Steve Jobs…
Could be 10X bigger than the iPad… the MacBook… and the iPhone… COMBINED.
In fact, it stands at the center of an emerging industry Bloomberg forecasts will grow as much as 19,254% in the coming years!
Early investors could make a fortune if they know where to position themselves…
And I've discovered a potential backdoor Apple play my research shows could 40X your money once this device goes live…
The best part is all you need is $5 to position yourself TODAY!
